levodopa has been researched along with l 745870 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Capiris, T; Connor, DT; Heffner, TG; MacKenzie, RG; Miller, SR; Pugsley, TA; Unangst, PC; Wise, LD | 1 |
| Aman, A; Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB | 1 |
| Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG | 1 |
3 other study(ies) available for levodopa and l 745870
| Article | Year |
|---|---|
Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cloning, Molecular; Cricetinae; Dopamine D2 Receptor Antagonists; Humans; Kinetics; Levodopa; Models, Chemical; Piperazines; Pyridines; Pyridones; Pyrroles; Rats; Receptors, Dopamine D2; Receptors, Dopamine D4; Structure-Activity Relationship; Sulfonamides | 1997 |
L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Drug Interactions; Dyskinesias; Female; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Pyridines; Pyrroles; Receptors, Dopamine D4 | 2012 |
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity | 2015 |